MannKind (NASDAQ:MNKD) Stock Price Up 4.9% - Here's What Happened

MannKind logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • MannKind shares rose 4.9% to about $4.14, while trading volume was 71% below its average.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $8.50; seven analysts rated the stock Buy, two Hold, and one Sell.
  • Quarterly EPS loss of $0.01 beat the $0.07 loss estimate, while revenue of $101.87 million missed expectations but increased 24% year over year.
  • Interested in MannKind? Here are five stocks we like better.

MannKind Corporation (NASDAQ:MNKD - Get Free Report) rose 4.9% on Tuesday. The stock traded as high as $4.09 and last traded at $4.1420. Approximately 1,467,584 shares changed hands during trading, a decline of 71% from the average daily volume of 5,045,177 shares. The stock had previously closed at $3.95.

Analysts Set New Price Targets

A number of brokerages have recently commented on MNKD. Weiss Ratings reissued a "sell (d)" rating on shares of MannKind in a research note on Friday, October 2nd. Wall Street Zen raised MannKind from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. HC Wainwright reissued a "buy" rating on shares of MannKind in a report on Thursday, July 23rd. Truist Financial decreased their price target on shares of MannKind from $6.00 to $5.00 and set a "buy" rating for the company in a research report on Wednesday, October 7th. Finally, Chardan Capital started coverage on shares of MannKind in a research note on Monday, October 19th. They set a "buy" rating and a $10.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Check Out Our Latest Research Report on MNKD

MannKind Stock Up 2.8%

The stock has a 50 day moving average of $3.57 and a 200 day moving average of $3.67. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -17.59 and a beta of 1.10.

MannKind (NASDAQ:MNKD - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.06. The firm had revenue of $101.87 million for the quarter, compared to the consensus estimate of $107.74 million. The firm's revenue for the quarter was up 24.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 EPS. As a group, sell-side analysts anticipate that MannKind Corporation will post -0.20 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Steven Binder sold 39,051 shares of the business's stock in a transaction on Friday, September 25th. The shares were sold at an average price of $3.29, for a total value of $128,477.79. Following the transaction, the director owned 713,258 shares in the company, valued at $2,346,618.82. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Independent Financial Group LLC acquired a new stake in MannKind during the first quarter worth approximately $31,000. Global Retirement Partners LLC boosted its holdings in shares of MannKind by 245.4% during the 3rd quarter. Global Retirement Partners LLC now owns 8,636 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 6,136 shares in the last quarter. AdvisorNet Financial Inc bought a new position in shares of MannKind during the 3rd quarter worth approximately $39,000. Sterling Capital Management LLC boosted its holdings in shares of MannKind by 864.1% during the 3rd quarter. Sterling Capital Management LLC now owns 10,422 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 9,341 shares in the last quarter. Finally, Waverly Advisors LLC acquired a new stake in shares of MannKind during the 1st quarter worth approximately $43,000. 49.55% of the stock is owned by institutional investors and hedge funds.

MannKind Company Profile

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MannKind Right Now?

Before you consider MannKind, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.

While MannKind currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines